IL-1alpha Targeted Modulation of CD14+CD16+ Monocytes
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to selectively target and modulate the proinflammatory CD14+CD16+ monocyte subset without causing significant immunosuppression, as existing therapies either deplete all monocyte populations or lack specificity, posing risks of severe immunosuppression.
Innovation Solution
Utilizing interleukin-1 alpha (IL-1alpha) as a marker to selectively target and modulate the CD14+CD16+ monocyte subset through agents that interfere with IL-1alpha binding or regulate its expression, such as antibodies or nucleic acids, to assess and treat diseases associated with these cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If existing therapies deplete all monocyte populations to treat disease, then disease-associated leukocytes are reduced, but severe immunosuppression occurs
Solution Approach 1:
The patent segments the monocyte population into distinct subsets based on CD14 and CD16 expression patterns (CD14++CD16-, CD14+CD16+, CD14-CD16+). By identifying and targeting specific subsets such as CD14+CD16+ monocytes that are pathogenic in certain diseases, the therapy achieves selective depletion of disease-associated cells while preserving other monocyte populations that are essential for normal immune function, thereby avoiding severe immunosuppression
Solution Approach 2:
The patent applies local quality by differentiating between various monocyte subsets with distinct functional properties and disease associations. Different subsets are targeted based on their specific roles: CD14+CD16+ monocytes are targeted in atherosclerosis due to their proinflammatory phenotype, while other subsets are preserved to maintain tissue repair and homeostatic functions. This subset-specific approach allows localized therapeutic action on pathogenic cells without global immunosuppression
2Object-affected harmful factors
If CD11/CD18 blockade is used to prevent leukocyte extravasation, then leukocyte infiltration is reduced, but generalized immunosuppression occurs due to Leukocyte adhesion deficiency risks
Solution Approach 1:
Rather than blocking the general CD11/CD18 adhesion system used by all leukocytes, the patent segments the approach by targeting specific monocyte subsets through their unique surface marker profiles (CD14 and CD16 combinations). This allows selective intervention on pathogenic monocytes while leaving the broader adhesion system intact, preventing the immunosuppression seen in Leukocyte adhesion deficiency
Solution Approach 2:
The patent uses specific surface markers (CD14 and CD16) as intermediary targets to achieve selective monocyte subset modulation. By designing therapies that recognize and target cells based on their specific CD14/CD16 expression patterns, the approach provides a more precise intermediary mechanism compared to broad CD11/CD18 blockade, enabling disease-specific cell targeting without generalized immunosuppression
Data Source
AI summary
The invention is based on the discovery that interleukin-1 alpha (IL-1alpha) is expressed on the proinflammatory CD14+CD16+ monocyte subset. Importantly, since IL-1alpha appears to be almost exclusively expressed on this monocyte subset and not other leukocytes, it represents an ideal marker for targeting the CD14+CD16+ monocyte subset. The effectiveness of an agent that depletes such pathogenic cells or modulates IL-1alpha function on such cells type can be monitored by assessing CD14+CD16+ monocyte levels or functionality.